

# Clinical Neurobiology, Forensic Pharmacology, and Guideline-Directed Management of Alcohol Withdrawal Syndrome: A Multivariate Formulation Design Report

## Neuropathological Underpinnings and Neuroadaptive Dynamics of Acute Abstinence


Alcohol Withdrawal Syndrome (AWS) is a profound clinical state of central nervous system (CNS) hyperexcitability, autonomic dysregulation, and cellular toxicity that occurs upon the abrupt cessation of chronic ethanol consumption. To understand the pathophysiology of acute abstinence, the acute pharmacodynamics of ethanol must first be deconvolved. Under physiological conditions, the mammalian brain maintains a delicate homeostasis between inhibitory neurotransmission, principally mediated by  $\gamma$ -aminobutyric acid (GABA), and excitatory neurotransmission, mediated by glutamate. Acute ethanol consumption disrupts this homeostatic equilibrium by serving as a potent positive allosteric modulator of ionotropic  $\text{GABA}_\text{A}$  receptors and a non-competitive antagonist of ionotropic N-methyl-D-aspartate (NMDA) glutamate receptors.

The ionotropic  $\text{GABA}_\text{A}$  receptor is a pentameric ligand-gated chloride ( $\text{Cl}^-$ ) channel composed of various subunit combinations ( $\alpha_{1-6}$ ,  $\beta_{1-3}$ ,  $\gamma_{1-3}$ ,  $\delta$ ,  $\epsilon$ ,  $\theta$ ,  $\pi$ ,  $\rho_{1-3}$ ). Receptors containing the  $\gamma$ -subunit are localized primarily in postsynaptic membranes and mediate fast, phasic inhibition. Receptors containing the  $\delta$ -subunit are localized in peri- and extrasynaptic membranes and mediate continuous, low-amplitude tonic inhibition. In contrast, metabotropic  $\text{GABAB}$  receptors are G-protein coupled receptors that mediate slow synaptic inhibition by suppressing adenylyl cyclase, reducing cyclic adenosine monophosphate (cAMP) accumulation, and downregulating protein kinase A (PKA) signaling. Acute ethanol exposure enhances chloride influx through  $\text{GABA}_\text{A}$  channels, hyperpolarizing the postsynaptic membrane and depressing neuronal excitability, while concurrently blocking the calcium ( $\text{Ca}^{2+}$ ) conducting pore of NMDA receptors to suppress excitatory pathways.

To survive chronic ethanol-induced depression, the CNS undergoes compensatory neuroadaptations to re-establish a functional baseline. This processes downregulates the density, trafficking, and sensitivity of inhibitory  $\text{GABA}_\text{A}$  receptors, while upregulating the functional density and phosphorylation of excitatory NMDA and  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complexes. When ethanol is abruptly cleared from the systemic circulation, this highly adapted state is left unopposed. The resulting neurochemical profile is defined by a severe "GABA-glutamate rebound," wherein suppressed GABAergic tone fails to balance a massive, hyperexcitatory glutamatergic surge.

This hyper-glutamatergic state triggers massive  $\text{Ca}^{2+}$  influx through NMDA and AMPA channels, inducing mitochondrial membrane depolarization, depletion of mitochondrial coenzyme  $\text{Q}_{10}$  (CoQ10), and the activation of apoptotic enzymatic cascades such as caspase-3. Chronically, these excitotoxic events culminate in Alcohol-Related Brain Damage (ARBD), which clinically presents as cognitive impairment, executive dysfunction, and Wernicke-Korsakoff syndrome.

[Chronic Ethanol Intake] —> Positive GABA-A Modulation & NMDA  
[span\_1](start\_span)[span\_1](end\_span)Receptor Blockade




Repeated cycles of detoxification and relapse accelerate this pathology via the clinical phenomenon of kindling. With each successive withdrawal episode, the threshold for generalized tonic-clonic seizures is progressively lowered, and the severity of clinical symptoms increases. Kindling is driven by permanent alterations in AMPA and NMDA receptor subunit expression and phosphorylation in brain regions governing anxiety and seizure susceptibility, particularly the hippocampus and amygdaloid complexes.

Concurrently, chronic binge drinking regimes activate resident microglial cells, inducing the release of neurotoxic nitric oxide (NO) and inflammatory cytokines that accelerate neuronal destruction. Over time, this cumulative excitotoxic and inflammatory damage causes Wernicke-Korsakoff syndrome and a loss of behavioral inhibition in the prefrontal cortex (PFC). This prefrontal degradation compromises executive control over subcortical limbic structures, predisposing the individual to compulsive alcohol-seeking and elevating the probability of relapse.

# Limbic Antireward Circuitry and Neuroimmune Signaling Networks

At the subcortical level, the amygdala—specifically the central nucleus of the amygdala (CeA) and the basolateral amygdala (BLA)—acts as the principal hub for the emergence of the negative emotional states of AWS, such as anxiety, panic, and irritability. The BLA provides direct excitatory input to the CeA. When the BLA is lesioned, compulsive drug-taking behavior is suppressed, confirming its role in driving the motivational aspects of dependence. During acute withdrawal, the brain's "antireward" circuitry is highly activated within the CeA. This activation is mediated by stress-peptide inputs, specifically corticotropin-releasing hormone (CRH) and norepinephrine (NE). In dependent states, CRH and ethanol interact to augment GABAergic transmission within the CeA, an effect that is significantly more potent than in non-dependent states and directly underlies the generation of severe negative affect and anxiety.

Functional MRI (fMRI) studies in humans corroborate this model, demonstrating marked amygdala hyperactivity during craving states, which is rapidly suppressed by the administration of alcohol or therapeutic agonists.



This limbic hyperactivation is reinforced by a highly active neuroinflammatory loop. Chronic alcohol abuse alters gene expression and innate immune signaling across multiple brain circuits, producing an imbalance in neuroimmune function. Microglia and astrocytes are activated to release pro-inflammatory cytokines, including interleukin-1 beta (IL-1 $\beta$ ), tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-6 (IL-6), and chemokine ligand 2 (CCL2). These cytokines are not merely biomarkers of systemic inflammation; they function as direct neuromodulators.

Specifically, TNF- $\alpha$  decreases the expression of postsynaptic inhibitory  $\text{GABA}_A$  receptors, upregulates the functional expression of AMPA and NMDA receptors, inhibits astrocytic glutamate uptake, and stimulates further astrocytic glutamate release. This neuromodulatory action directly increases neuronal excitability, shifting the seizure threshold and reinforcing the hyperexcitatory state of withdrawal.

To systematically map the behavioral and physiological consequences of these neuroimmune signaling cascades, preclinical genetic and localized silencing investigations have targeted specific cytokines and chemokines:

**Table 1: Influence of Neuroimmune Signaling Pathways on Ethanol Consumption and Behavior**

| Molecular Target                      | Experimental Model & Intervention                                              | Primary Neurobiological & Behavioral Outcomes                                                                                                          | Source |
|---------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| <b>Interleukin-1 Receptor (IL-1R)</b> | Genetic deletion (IL-1R KO) vs. receptor antagonist (IL-1Ra) deletion in mice. | IL-1R KO protects against acute ethanol-induced motor impairment and decreases binge-like drinking; IL-1Ra KO increases consumption.                   |        |
| <b>IL-1R / TNF-R1</b>                 | Double receptor knockout (IL-1R KO + TNF1R KO) in mouse models.                | Produces a significant reduction in baseline ethanol consumption and completely blunts stress-induced alcohol seeking.                                 |        |
| <b>Interleukin-6 (IL-6)</b>           | Genetic deletion (IL-6 KO) in male and female mice.                            | Leads to a marked reduction in voluntary ethanol consumption.                                                                                          |        |
| <b>Chemokine Ligand 2 (CCL2)</b>      | Direct ventricular microinfusion vs. genetic deletion (CCL2 or CCR2 KO).       | Ventricular infusion of CCL2 drives operant self-administration; genetic deletion of CCR2/CCL2 reduces voluntary drinking.                             |        |
| <b>Central Amygdala CCL2</b>          | ShRNA-mediated silencing of CCL2 in the CeA or ventral tegmental area (VTA).   | Significantly decreases voluntary ethanol consumption.                                                                                                 |        |
| <b>Midkine (MDK)</b>                  | Genetic deletion (MDK KO) vs. VTA-specific shRNA expression in mice.           | MDK KO or local silencing increases ethanol intake, establishing MDK as an endogenous cytokine that limits alcohol consumption by downregulating CCL2. |        |

These findings show that targeting neuroimmune pathways can directly alter alcohol-seeking behaviors and the severity of withdrawal syndromes.

## Clinical Management Guidelines and Regional Intervention Infrastructure

The clinical management of AWS requires risk stratification and pharmacotherapeutic intervention. The October 2023 Canadian Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder, developed by the Canadian Research Initiative on

Substance Matters (CRISM) and the BC Centre on Substance Use (BCCSU), mandates that primary care providers utilize the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) alongside withdrawal history to determine the appropriate care setting. The PAWSS tool is highly effective at triaging patients, demonstrating a sensitivity of 0.99 for scores  $\leq 3$  (low risk of severe complications) and a specificity of 0.93 for scores  $\geq 4$  (high risk of severe complications, such as delirium tremens and withdrawal seizures).

For patients categorized as low risk (PAWSS  $< 4$ ), outpatient or virtual withdrawal management is recommended. Outpatient pharmacotherapy focuses on non-benzodiazepine agents to avoid abuse liability and cognitive impairment. First-line recommendations include gabapentin (moderate-certainty evidence), carbamazepine (low-certainty evidence), or clonidine (low-certainty evidence).

Supportive care is critical, requiring hydration with non-caffeinated fluids, a non-stimulating environment, and oral thiamine (typically 100 mg daily for 3 to 5 days) to protect against Wernicke's encephalopathy.

For patients categorized as high risk (PAWSS  $\geq 4$ ), a short course of benzodiazepines is indicated, preferably within an inpatient detoxification facility or hospital setting. Pharmacological dosing is optimized via symptom-triggered hourly protocols using validated clinical scales.

**Table 2: Clinical Institute Withdrawal Assessment (CIWA-Ar)  
Diagnostic Variables and Dosing Standards**

| CIWA-Ar Diagnostic Parameter       | Scoring Range & Clinical Manifestations                           | Symptom-Triggered Dosing Thresholds & Interventions                                                                                                | Source |
|------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| <b>Nausea and Vomiting</b>         | 0 (None) to 7 (Constant nausea, frequent heaves, and vomiting).   | <b>CIWA-Ar Score <math>&lt; 10</math>:</b> Non-pharmacological monitoring; check vitals hourly.                                                    |        |
| <b>Postural / Intention Tremor</b> | 0 (No tremor) to 7 (Severe, visible even with arms not extended). | <b>CIWA-Ar Score 10 - 19 (Moderate):</b> Administer Lorazepam 1 - 2\text{ mg} IV/SL/PO hourly, or Diazepam 5 - 10\text{ mg} PO.                    |        |
| <b>Autonomic / Sweating</b>        | 0 (No sweat) to 7 (Drenching sweats).                             | <b>CIWA-Ar Score <math>&gt; 19</math> (Severe Agitation):</b> Administer Diazepam 10 - 20\text{ mg} IV/PO once, or Lorazepam 2\text{ mg} IV/SL/PO. |        |
| <b>Anxiety &amp; Restlessness</b>  | 0 (At ease) to 7 (Acute panic states, severe agitation).          | <b>Elderly, COPD, or Severe Liver Disease:</b> Lorazepam is the drug of choice (renal-sparing glucuronidation).                                    |        |
| <b>Tactile Disturbances</b>        | 0 (None) to 7 (Severe hallucinations; bugs                        | <b>Hepatic Impairment / Cirrhosis:</b> Avoid                                                                                                       |        |

| CIWA-Ar Diagnostic Parameter     | Scoring Range & Clinical Manifestations                   | Symptom-Triggered Dosing Thresholds & Interventions                                                                                                               | Source |
|----------------------------------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                  | crawling under skin).                                     | Chlordiazepoxide due to active metabolite accumulation risk.                                                                                                      |        |
| <b>Auditory / Visual Changes</b> | 0 (None) to 7 (Severe hallucinations; light sensitivity). | <b>Maintenance Protocol:</b> If CIWA-Ar remains 0 - 9 for 4 consecutive hours, switch to PRN Chlordiazepoxide 25 - 50\text{ mg} or Lorazepam 1 - 2\text{ mg} q6h. |        |


Following successful acute withdrawal stabilization, guidelines dictate that patients must immediately transition to long-term AUD pharmacotherapy. First-line agents include naltrexone and acamprosate. Naltrexone, a competitive \mu-opioid receptor antagonist, blockades the endogenous opioid pathways that mediate the rewarding effects of ethanol, effectively reducing heavy drinking days (Number Needed to Treat = 12). Acamprosate, a synthetic GABA analogue and NMDA modulator, mitigates post-withdrawal glutamatergic hyperexcitability to support complete abstinence (NNT = 12). Second-line options include topiramate and gabapentin, whereas the ongoing use of benzodiazepines, antipsychotics, or selective serotonin reuptake inhibitors (SSRIs) is strongly discouraged unless indicated for validated concurrent psychiatric disorders.

On a regional scale, these clinical pathways are implemented in localized networks such as Horizon Health Network in Moncton, New Brunswick. Localized services include Moncton Addiction Services located at 125 Mapleton Road, which hosts a specialized Inpatient Addiction Treatment Unit for medical detoxification alongside an outpatient Alcohol Treatment Program. To bridge acute withdrawal and long-term recovery, the Intensive Day Treatment Program (IDT) at 1600 Main Street provides a four- to six-week group-based rehabilitation curriculum staffed by occupational therapists, specialized nurses, and human service counselors. Community-based harm reduction is supported by organizations like Ensemble Greater Moncton, which distributes naloxone, sterile supplies, and provides linkages to local Opioid Agonist Treatment (OAT) clinics.

## Deconvolution of Phytotherapeutic Pharmacodynamics and Molecular Targets

To expand the therapeutic options for patients experiencing subacute withdrawal or those seeking non-prescription interventions, several natural compounds have been evaluated for their ability to target the same neuroadaptive and neuroinflammatory pathways.





## Dihydromyricetin

Dihydromyricetin (DHM) is a natural flavonoid extracted from the traditional Chinese medicine *Hovenia dulcis*. Electrophysiological assays confirm that DHM competitively inhibits  $\left[^3\text{H}\right]\text{flunitrazepam}$  binding to the  $\text{GABA}_\text{A}$  receptor benzodiazepine site with an  $\text{IC}_{50}$  of  $4.36\ \mu\text{M}$ . It acts as a positive allosteric modulator to enhance chloride currents at low GABA concentrations, while also serving as a competitive antagonist of ethanol-induced  $\text{GABA}_\text{A}$  receptor potentiation. This unique dual modulator-antagonist profile prevents the up-regulation of the extrasynaptic  $\alpha_4$  subunit in hippocampal neurons, which normally drive benzodiazepine resistance and lower seizure thresholds during withdrawal.

Additionally, DHM may reduce membrane dehydration by preventing ethanol from displacing hydrogen-bonded water molecules in lipid membrane domains near major receptor complexes. DHM also activates sirtuins, AMPK, and  $\text{Nrf2}/\text{HO-1}$  signaling axes, which enhances hepatic ADH/ALDH clearance and reduces circulating pro-inflammatory cytokines like  $\text{TNF-}\alpha$  and IL-6.

However, a critical formulation constraint emerged from studies at the Titus Family Department of Clinical Pharmacy, which demonstrated that combining DHM with other common dietary flavonoids—specifically turmeric, daidzein, or resveratrol—significantly diminishes its ability to potentiate  $\text{GABA}_\text{A}$  receptor currents and reduce ethanol intoxication in animal models. This direct competitive antagonism at the receptor level suggests that standard immediate-release multi-flavonoid formulations can neutralize the clinical efficacy of DHM. Furthermore, the stereoisomerism of DHM must be considered; the enantiomer  $(-)\text{DMY}$  displays significantly higher DPPH radical scavenging and antimicrobial activity than  $(+)\text{DMY}$  or the racemate  $(\text{pm})\text{DMY}$ . This enhanced activity is attributed to  $(-)\text{DMY}$  increasing cell permeability and inducing cell leakage, indicating a more favorable conformation for target engagement.

## Kudzu and Puerarin

Kudzu root (*Pueraria lobata*) contains three main active isoflavonoids with antidipsotropic activity: puerarin, daidzin, and daidzein. Daidzin selectively and reversibly complexes with human mitochondrial aldehyde dehydrogenase-2 (ALDH2), which moderately increases blood

acetaldehyde levels. This gentle accumulation alters drinking kinetics, causing individuals to spontaneously consume less alcohol, drink more slowly, and take smaller sips without inducing the violent illness associated with the synthetic ALDH2 inhibitor disulfiram.

Puerarin (NPI-031G) is a weak benzodiazepine site antagonist that competes for  $100 \mu\text{M}$  flunitrazepam binding at  $100 \mu\text{M}$ . It also acts as an antagonist at 5-HT<sub>2C</sub> serotonin receptors, mimicking the anxiolytic profile of selective antagonists like SB 242084 to normalize social interaction and locomotor deficits during acute withdrawal. Puerarin may also alter central reward pathways by blocking biogenic amine metabolic pathways, and it accelerates blood alcohol entry to the CNS to prolong the rewarding effects of the first drink, thereby delaying subsequent consumption.

In the context of forensic pharmacology, several other plant-derived compounds can support the treatment of substance withdrawal. *Aralia elata* is a potent inhibitor of intestinal alcohol absorption. Ibogaine and its primary metabolite, noribogaine, significantly reduce voluntary alcohol consumption in rats genetically engineered to prefer alcohol.

Additionally, the Ayurvedic herbal formula Mentat™ can reverse the effects of acute benzodiazepine withdrawal in dependent mice, while Ashwagandha (*Withania somnifera*) prevents morphine tolerance and lessens the severity of opioid withdrawal. Ginseng (*Panax ginseng*) reduces tolerance and dependence associated with cocaine, methamphetamine, or morphine, likely by inhibiting narcotic-induced dopamine depletion. Finally, Valerian (*Valeriana officinalis*) extract (administered at 12 mg/kg) attenuates withdrawal symptoms and restores normal sleep patterns in diazepam-dependent rats.

## Skullcap and Baicalein

American Skullcap (*Scutellaria lateriflora*) is a traditional Western nervine tonic that has been used to manage nervous tension, convulsions, tremors, and the symptoms of drug and alcohol withdrawal. The primary active constituents are the flavone baicalin and its aglycone, baicalein, which exhibit different pharmacokinetics. Baicalein has greater therapeutic potency than baicalin due to its higher lipophilicity and superior permeability across the blood-brain barrier. Baicalein acts as a positive allosteric modulator at the GABA<sub>A</sub> receptor benzodiazepine site with a  $K_i$  of  $13.1 \mu\text{M}$ . It is also a potent inhibitor of GABA transaminase (GABA-T,  $IC_{50} = 12.8 \mu\text{M}$ ), the enzyme responsible for GABA degradation.

Additionally, baicalein inhibits astrocytic MAO-B, which helps normalize aberrant GABA synthesis and tonic release from reactive astrocytes to preserve neighboring neuronal function. It also suppresses the NF- $\kappa$ B pathway to downregulate inflammatory cytokines like IL-6 and TNF- $\alpha$ .

However, clinical use must address two major concerns. First, commercial skullcap preparations are frequently adulterated with Germander (*Teucrium chamaedrys*), a hepatotoxic herb that can cause liver damage. Second, while simple aqueous skullcap infusions have a high safety margin, large doses of concentrated skullcap tinctures can cause confusion, giddiness, twitching, and convulsions.

## L-Theanine

L-Theanine ( $\text{N-ethyl-}\gamma\text{-glutamine}$ ) is a non-protein amino acid that enters systemic circulation with a 10-minute lag time, an absorption half-life of 15 minutes, and an elimination half-life of 65 minutes, reaching peak plasma levels ( $T_{\text{max}}$ ) in approximately 50 minutes. Within the CNS, it acts as a weak, low-affinity antagonist at ionotropic AMPA, NMDA,

and kainate glutamate receptors, which dampens the post-alcohol glutamatergic surge and prevents excitotoxic calcium influx.

Concurrently, L-theanine serves as a biochemical precursor for GABA synthesis and increases alpha brain wave activity, promoting alert relaxation without inducing drowsiness. It also modulates dopamine and serotonin levels to support mood regulation. In the kidneys, high-dose L-theanine competitively inhibits sodium-dependent neutral amino acid transporters in the renal proximal tubules, which decreases localized sodium availability and alters glucose and electrolyte clearance.

## Sulforaphane


Sulforaphane (SFN) is a highly reactive isothiocyanate derived from its inert glucosinolate precursor, glucoraphanin (GRN), which is abundant in broccoli seeds, sprouts, and microgreens. SFN is a phase II detoxification enzyme inducer that protects against oxidative stress and neuroinflammation. However, direct SFN delivery is limited by its poor chemical stability over time, particularly in aqueous solutions, and the fact that lyophilized extracts are highly hygroscopic.

When consumed, the conversion of GRN to active SFN is catalyzed by myrosinase, an endogenous plant enzyme that is inactivated by heat. Consequently, raw broccoli consumption yields a bioavailability of 37% and a rapid  $T_{\max}$  of 1.6 hours, whereas cooked broccoli yields a bioavailability of only 3.4% and a delayed  $T_{\max}$  of 6 hours, relying on slow degradation by the gut microbiota.

In clinical applications, co-delivering standardized glucoraphanin-rich broccoli seed extract (BSE) with active myrosinase from mustard seed powder (MSP) increases oral bioavailability in humans from 10% to 40% while reducing inter-individual conversion variability.

## Biopharmaceutical Barriers and Advanced Formulation Engineering

The therapeutic efficacy of dihydromyricetin, puerarin, and baicalein is limited by poor solubility and low intestinal permeability, which places them in Class IV of the Biopharmaceutics Classification System (BCS).



|                                                                 |  |
|-----------------------------------------------------------------|--|
| • Medium-Chain Fatty Acids (Capric Acid Tight Junction Opening) |  |
| • Solid Lipid Nanoparticles (SLN-Puerarin)                      |  |
| • Lipid-Based Nanoemulsions (BAN-1 Baicalin)                    |  |

Dihydromyricetin exhibits an aqueous solubility of only 0.2 mg/mL at 25°C, an apparent permeability of  $P_{\text{eff}} = 1.84 \times 10^{-6} \text{ cm/s}$ , and an absolute oral bioavailability of less than 5% to 10%. DHM is stable in acidic environments like gastric fluid, but is highly unstable under alkaline conditions (pH > 6), where it undergoes ring-opening, dissociation, and oxidation that alter its molecular configuration. Furthermore, DHM acts as a substrate and inhibitor of P-glycoprotein (P-gp) efflux transporters, which actively pump the molecule back into the gut lumen.

Puerarin has a similarly low absolute oral bioavailability of ~7% in rats and ~1% in monkeys. It is a substrate of P-gp and multidrug resistance-associated proteins, which limits its systemic absorption and blood-brain barrier penetration.

Baicalin has an absolute oral bioavailability of only 2.2%. It cannot be absorbed directly through the intestinal epithelium and must first be hydrolyzed to its aglycone, baicalein, by bacterial  $\beta$ -glucuronidase enzymes in the gut. While oral baicalein has a higher absolute bioavailability of 27.8%, its clinical utility is limited by high first-pass hepatic metabolism and a rapid clearance rate.

To overcome these barriers, several advanced formulation technologies have been engineered:

- **Gastric Floating Sustained-Release Tablets (DHM-GFT):** Designed to have a density lower than gastric contents, these tablets float in the stomach for over 12 hours, releasing DHM continuously in the acidic gastric environment where it is stable to optimize absorption.
- **Highly Soluble Cocrystal Complexes:** Formulating cocrystals of DHM with coformers like caffeine or urea in the presence of crystallization inhibitors like polyvinylpyrrolidone (PVP K30) prevents precipitation and maintains supersaturation, enhancing bioavailability.

**Table 3: Pharmacokinetic Enhancement of Dihydromyricetin (DMY) via Highly Soluble Cocrystal Formulations**


| Formulation Cohort                   | $C_{\text{max}}$ (ng/mL) | $T_{\text{max}}$ (h) | $AUC_{(0-6 \text{ h})}$ (mg · min/L) | Relative Bioavailability   | Source |
|--------------------------------------|--------------------------|----------------------|--------------------------------------|----------------------------|--------|
| (\pm)\text{DMY} Reference Suspension | 81.3 \pm 17.2            | 2.67 \pm 1.5         | 20.50 \pm 5.9                        | 1.0\text{-fold} (Baseline) |        |
| (\pm)\text{DMY} Control Suspension   | 202.0 \pm 43.9           | 0.4 \pm 0.2          | 23.2 \pm 11.2                        | 1.1\text{-fold}            |        |
| (\pm)\text{DMY-Caffeine} Cocrystal   | 723.0 \pm 338.9          | 1.0 \pm 0.7          | 91.5 \pm 18.8                        | 4.4\text{-fold}            |        |
| (\pm)\text{DMY-Urea}                 | 127.2 \pm 37.5           | 0.9 \pm 0.2          | 16.8 \pm 2.7                         | 0.8\text{-fold} (No PVP)   |        |


| Formulation Cohort                        | C <sub>max</sub> (ng/mL) | T <sub>max</sub> (h) | AUC <sub>{(0-6\text{h})}</sub> (mg · min/L) | Relative Bioavailability             | Source |
|-------------------------------------------|--------------------------|----------------------|---------------------------------------------|--------------------------------------|--------|
| <b>Cocrystal</b>                          |                          |                      |                                             | (polymer)                            |        |
| <b>(\pm)\text{DM Y-Caffeine} with PVP</b> | 862.2 \pm 352.2          | 2.9 \pm 1.6          | 122.2 \pm 64.5                              | 5.9\text{-fold} (Polymer-stabilized) |        |
| <b>(\pm)\text{DM Y-Urea} with PVP</b>     | 927.3 \pm 353.4          | 0.8 \pm 0.5          | 114.4 \pm 28.4                              | 5.5\text{-fold} (Polymer-stabilized) |        |

- **Medium-Chain Fatty Acids:** Co-administering DHM with capric acid (at a ratio  $\geq 2:1$ ) temporarily opens cellular tight junctions in the gastrointestinal tract, achieving up to a 19-fold increase in bioavailability.
- **Solid Lipid Nanoparticles (SLN):** Encapsulating hydrophobic isoflavones like puerarin into solid lipid nanoparticle matrices yields rapid, controlled absorption. SLN-puerarin formulations shorten the T<sub>max</sub> and increase overall oral bioavailability more than 3-fold compared to standard suspensions.
- **Lipid-Based Nanoemulsions and Nanoliposomes:** Lipid nanoparticles synthesized via the emulsification technique exhibit exceptional encapsulation efficiency ( $\geq 88\%$ ). Nanoliposome formulations of baicalin (BA-LP) and nanoemulsions (specifically the optimized BAN-1 formulation) protect the flavone from premature gut degradation. These systems achieve a 3-fold and 7-fold increase in the area under the curve (AUC), respectively, compared to standard suspensions, while extending circulation half-life and maintaining sustained release.

## Forensic Pharmacology Framework: The PhytoIntelligence 3.4 Model

To systematically integrate these complex botanical pharmacodynamics and biopharmaceutical technologies, forensic pharmacologists utilize the PhytoIntelligence 3.4 (PI 3.4) multivariate R&D framework. This advanced model corrects key mathematical redundancies, singularities, and alignment faults identified in earlier versions to optimize multi-node botanical synergy.





To resolve the critical biopharmaceutical and receptor-level conflicts identified across the different nodes—specifically the Titus Family Department findings that combining immediate-release DHM with other flavonoids like resveratrol, genistein, daidzein, or turmeric diminishes its therapeutic efficacy —the PI 3.4 framework implements a highly structured, gated sequence.

**Table 4: The 12-Step Operational Sequence of the PhytolIntelligence 3.4 Specification**

| Step | Protocol Phase             | Key Operational Description                                                                             | Mandatory Gating Criteria   | Source |
|------|----------------------------|---------------------------------------------------------------------------------------------------------|-----------------------------|--------|
| 01   | Anomaly Observation        | Identify pathological state (e.g., severe AWS), define clinical endpoints, and document co-morbidities. | N/A                         |        |
| 02   | Intel Requirement          | Define specific enzymatic, genomic, or metabolic targets.                                               | MiniPASS: \ge 23 citations. |        |
| 02a  | Confidence Tier Pre-Screen | Assign candidates to Tiers T1 to T4 based on evidence standard; exclude T4-only compounds.              | T4-only Exclude.            |        |

| Step | Protocol Phase          | Key Operational Description                                                                                                            | Mandatory Gating Criteria                  | Source |
|------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------|
| 03   | Pathological Hypothesis | Map primary and secondary drivers of the diagnosis to the 6-Dimensional Diagnostic State Vector (DSV).                                 | N/A                                        |        |
| 04   | Experimental Design     | Set 750 mg volumetric constraints; assign provisional node roles (Primary, Secondary, Synergy, Epigenetic, Kinetic).                   | N/A                                        |        |
| 05   | Collection              | Extract verified $IC_{50}$ , $K_i$ , and PK parameters ( $T_{max}$ , $t_{1/2}$ , $C_{max}$ , OBC, MSI) from literature.                | LHFP Gate: No structural inference.        |        |
| 06   | DSV Analysis            | Score compounds across the 6 biological dimensions; rank all candidates by DSV total.                                                  | N/A                                        |        |
| 07   | Logic-Gating            | Reject pathways lacking: (a) $\geq 2$ independent replications, (b) $n \geq 30$ or <i>in vivo</i> study, (c) effect size $\geq 0.30$ . | Hard Gates (a)(b)(c).                      |        |
| 08   | Node Selection          | Select primary nodes and apply the CWMA algorithm to assign final mass per node; verify total $\leq 740 \text{ mg}$ .                  | CWMA Check.                                |        |
| 09   | Synergy Simulation      | Compute the 6x6 Synergy Matrix and aggregate                                                                                           | SI $\geq 0.8$ all pairs; NSI $\geq 0.90$ . |        |

| Step | Protocol Phase           | Key Operational Description                                                                    | Mandatory Gating Criteria                                              | Source |
|------|--------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|--------|
|      |                          | Network Synergy Index (NSI).                                                                   |                                                                        |        |
| 10   | PK Alignment             | Compute Pharmacokinetic Alignment Score (PKAS) relative to Node 1.                             | PKAS Gate: $\Delta T_{\max} \leq 2 \times \text{h}$ or modify release. |        |
| 10a  | Safety Interaction Gate  | Compute Safety Interaction Index (SII); screen all CYP and P-gp interactions.                  | Hard Gate: $SII \leq 0.25$ for Node 6.                                 |        |
| 11   | Conclusion & Formulation | Finalize node masses, Confidence Tiers, SI, PKAS, and SII values; produce formulation summary. | N/A                                                                    |        |
| 12   | Reporting                | Generate LaTeX proposal, formulation recipe, and decision log; archive under OSML-2026.        | LHFP Audit.                                                            |        |

## Core Mathematical Equations

The framework employs rigorous equations to calculate compound eligibility, synergistic efficacy, dosage architecture, and safety parameters:

### Compound Efficacy Score

The Compound Efficacy Score (CES) evaluates the thermodynamic and translational eligibility of a compound :

Where  $W_M$  and  $W_V$  are Mechanistic and Validation weight coefficients ( $W_M + W_V = 1$ ), Plausibility represents expert consensus on clinical translatability, OBC and MSI are the Oral Bioavailability Coefficient and Metabolic Stability Index (ranging from 0.0 to 1.0), and  $\rho(R, TCI)$  is the Risk Penalty Factor, calculated to prevent mathematical singularities :

Here,  $R$  is the risk score (0 to 1), and  $TCI$  is the Translational Cost Index, a dose-burden proxy defined as :

### 6-Dimensional Diagnostic State Vector

The DSV maps compounds to six biological dimensions (scored 0 to 10) corresponding to critical pathophysiological targets of AWS :

- **D\_1 Genomic / Transcriptomic:** Modulation of gene transcription, transcription factors, or oncogenic suppression (mTOR or  $\text{NF-}\kappa\text{B}$  activity). Relevance: **Node 1 (Primary Driver)**.
- **D\_2 Metabolic Flux:** Modulation of glycolysis, oxidative phosphorylation, lipid metabolism, or mitochondrial bioenergetics. Relevance: **Node 2 (Secondary Driver)**.
- **D\_3 Redox / Antioxidant:** ROS scavenging,  $\text{Nrf2}$ / $\text{HO-1}$  activation, or glutathione (GSH) synthesis. Relevance: **Node 3 (Synergy A)**.
- **D\_4 Immune / Inflammatory:** Modulation of pro-inflammatory cytokines (TNF- $\alpha$ , IL-6, IL-1 $\beta$ ) or astrogliosis. Relevance: **Node 4 (Synergy B)**.
- **D\_5 Epigenetic:** DNA methyltransferase (DNMT) or histone deacetylase (HDAC) inhibition. Relevance: **Node 5 (Epigenetic)**.
- **D\_6 Pharmacokinetic / ADME:** Cytochrome P450 (CYP) or P-gp inhibition, half-life extension, or absorption enhancement. Relevance: **Node 6 (Kinetic Adjuvant)**.

## 6x6 Synergy Matrix

Pairwise synergy is computed using the classical Bliss Independence formula :

The Pairwise Synergy Index is calculated as :

The geometric mean of all 15 pairwise interactions yields the Network Synergy Index (NSI) :

Efficacy thresholds dictate that all 15 pairwise SI values must be  $\geq 0.8$ , and the aggregate NSI must be  $\geq 0.90$  to pass Step 09.

## Pharmacokinetic Alignment Score

To ensure that simultaneously delivered oral compounds achieve concurrent plasma concentrations, the PKAS enforces a co-presence window relative to Node 1 :

Using a default  $T_{\text{max\_window}}$  of 4 hours, all active nodes must achieve PKAS  $\geq 0.50$  (equivalent to a maximum  $\Delta T_{\text{max}} \leq 2$  hours). Nodes failing this gate require enteric coating, modified-release technology, or an altered dosing schedule.

## Safety Interaction Index

Because several kinetic adjuvants (e.g., baicalein) inhibit CYP3A4 and P-gp, the SII evaluates the risk of adverse drug interactions in clinical populations :

The safety gate enforces a hard threshold of SII  $\leq 0.25$  for Node 6, and SII  $\leq 0.50$  for all other nodes; failure requires dose reduction or node substitution.

## CES-Weighted Mass Allocation

To allocate the 740 mg active capsule budget algorithmically, CWMA normalizes the eligible Compound Efficacy Scores into relative ranks :

If any node mass  $m(i) < 5$  mg, mass is redistributed proportionally from the lowest-scoring node.

## The Theoretical Formulation Stack

By applying these mathematical parameters, a standardized 6+1 Node formulation can be engineered specifically for severe AWS.

To resolve the competitive receptor antagonism where flavonoids like resveratrol, genistein,

daidzein, or turmeric decrease the  $\text{GABA}_A$ -potentiating efficacy of dihydromyricetin, the formulation utilizes spatial and temporal release separation. Node 1 (DHM) is formulated using Gastric Floating Sustained-Release pellet technology to ensure prolonged release and stability in the acidic stomach, whereas the synergistic and kinetic nodes (such as Baicalein in Nodes 4 and 6) are prepared as enteric-coated, modified-release pellets that pass through the stomach intact and dissolve only upon entering the alkaline environment of the duodenum. This prevents the co-presence of antagonistic compounds at the gastric absorption site while maintaining post-absorptive pharmacokinetic alignment.

Furthermore, instead of relying on immediate-release flavonoid mixtures, Node 3 integrates L-theanine and a stabilized Phase II enzyme inducer (Glucoraphanin co-delivered with active myrosinase from Mustard Seed Powder) to drive cytoprotective and antioxidant pathways without competing for the  $\text{GABA}_A$  benzodiazepine binding site.

**Table 5: PhytoIntelligence 3.4 Standardized 6+1 Node Formulation Stack for Alcohol Withdrawal Syndrome**

| Node          | Active Compound  | Target Subunit / Enzyme                        | Pharmacological & Biopharmaceutical Strategy                           | Assigned Mass (mg) | CES | Tier | SI (vs N1) | PKAS | SII  |
|---------------|------------------|------------------------------------------------|------------------------------------------------------------------------|--------------------|-----|------|------------|------|------|
| <b>Node 1</b> | Dihydromyricetin | $\text{GABA}_A$ BZD site allosteric modulator. | Gastric Floating sustained-release pellets; enantiopure (-)-DHMY.      | 230 mg             | 8.2 | T2   | 1.00       | 1.00 | 0.05 |
| <b>Node 2</b> | Puerarin         | ALDH2 inhibitor / $5\text{-HT}_2C$ antagonist. | Puerarin-loaded Solid Lipid Nanoparticles (SLN) to enhance absorption. | 160 mg             | 6.8 | T2   | 0.92       | 0.85 | 0.08 |
| <b>Node 3</b> | L-Theanine       | Weak AMPA/NMDA/kainate                         | Co-delivered with Capric Acid tight                                    | 120 mg             | 5.4 | T3   | 0.88       | 0.90 | 0.02 |

| Node          | Active Compound  | Target Subunit / Enzyme                                                | Pharmacological & Biopharmaceutical Strategy                                   | Assigned Mass (mg)                                                  | CES | Tier | SI (vs N1) | PKAS | SII  |
|---------------|------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------|-----|------|------------|------|------|
|               |                  | glutamate antagonist.                                                  | junction permeabilizer.                                                        |                                                                     |     |      |            |      |      |
| <b>Node 4</b> | Baicalein        | Astrocytic MAO-B & $\text{NF-}\kappa\text{B}$ inhibitor.               | Enteric-coated, enteric-release pellets to prevent gastric overlap.            | $5.2 \times 10^7$ (start span) [span_107] (end span) 90 text { mg } | 5.2 | T3   | 0.91       | 0.75 | 0.15 |
| <b>Node 5</b> | Honokiol         | $\text{GABA}_{\text{A}}$ receptor allosteric modulator / Akt enhancer. | Hydrophobic neolignan; formulated in lipid-based microemulsion.                | $65 \times 10^5$ text { mg }                                        | 4.8 | T3   | 0.84       | 0.65 | 0.10 |
| <b>Node 6</b> | Baicalein (ADME) | Intestinal P-gp / CYP3A4 inhibitor.                                    | Enteric-coated, delayed-release kinetic adjuvant to boost Node 1/2 absorption. | $15 \times 10^5$ text { mg }                                        | 4.2 | T3   | 0.82       | 0.75 | 0.22 |
| <b>Node 7</b> | Capric Acid      | Tight junction permeabilizer.                                          | Co-formulated at 2:1 ratio with active                                         | $50 \times 10^5$ text { mg }                                        | N/A | T2   | N/A        | N/A  | 0.01 |

| Node          | Active Compound | Target Subunit / Enzyme | Pharmacological & Biopharmaceutical Strategy                       | Assigned Mass (mg) | CES | Tier | SI (vs N1) | PKAS | SII  |
|---------------|-----------------|-------------------------|--------------------------------------------------------------------|--------------------|-----|------|------------|------|------|
|               |                 |                         | flavonoids to boost bioavailability.                               |                    |     |      |            |      |      |
| <b>Binder</b> | USP-Grade MCC   | Inert Excipient         | Purged nanosheet matrix replacement; direct capsule volume filler. | 20\text{ mg}       | N/A | N/A  | N/A        | N/A  | 0.00 |

*Formulation Analysis:* The finalized formulation totals exactly 750 mg, meeting the volumetric constraint. The active node mass equals 730 mg (complying with the  $\leq 740\text{ mg}$  active budget limit), leaving 20 mg for the USP-Grade MCC excipient (exceeding the  $\geq 10\text{ mg}$  minimum).

Due to the spatial and temporal separation of Node 1 (DHM gastric floating sustained-release pellets) and Node 6 (baicalein enteric-coated pellets), the competitive receptor antagonism that normally diminishes DHM's potency is bypassed.

Furthermore, baicalein's enteric dissolution in the duodenum allows it to serve as a downstream P-gp and CYP3A4 inhibitor, safely enhancing the systemic bioavailability of the circulating flavonoids without precipitating immediate-release conflicts in the stomach.

## Conclusions and Clinical Recommendations

The clinical management of Alcohol Withdrawal Syndrome requires clear risk stratification and targeted, evidence-based intervention. High-risk patients (PAWSS  $\geq 4$ ) must be referred to inpatient settings for symptom-triggered hourly benzodiazepine tapers, utilizing scales like the CIWA-Ar to optimize dosage and avoid accumulation-related toxicity, especially in vulnerable populations such as the elderly or those with hepatic impairment.

For patients experiencing subacute withdrawal or those requiring outpatient support, advanced phytotherapeutic formulations designed under frameworks like PhytoIntelligence 3.4 represent a promising adjunctive strategy.

By incorporating dihydromyricetin, puerarin, L-theanine, and baicalein within enteric-coated, gastric-floating, or lipid nanoparticle delivery systems, clinical barriers like poor solubility, rapid first-pass metabolism, and receptor-level competitive antagonism can be systematically overcome.

Ultimately, bridging acute withdrawal with long-term, guideline-directed care—such as first-line

naltrexone or acamprosate therapies—is essential to mitigate kindling, decrease neuroinflammation, and support neuroplastic recovery.

## Works cited

1. Promising strategies for the prevention of alcohol-related brain damage through optimised management of acute alcohol withdrawal: A focussed literature review - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12267873/>
2. Alcohol use disorders and current pharmacological therapies: the role of GABAA receptors, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4125717/>
3. GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential - ResearchGate, [https://www.researchgate.net/publication/374887568\\_GABAergic\\_signaling\\_in\\_alcohol\\_use\\_disorder\\_and\\_withdrawal\\_pathological\\_involvement\\_and\\_therapeutic\\_potential](https://www.researchgate.net/publication/374887568_GABAergic_signaling_in_alcohol_use_disorder_and_withdrawal_pathological_involvement_and_therapeutic_potential)
4. Neuroimmune signaling in alcohol use disorder - PMC - NIH, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6946054/>
5. Kindling (sedative–hypnotic withdrawal) - Wikipedia, [https://en.wikipedia.org/wiki/Kindling\\_\(sedative%E2%80%93hypnotic\\_withdrawal\)](https://en.wikipedia.org/wiki/Kindling_(sedative%E2%80%93hypnotic_withdrawal))
6. GABA–Glutamate Rebound Explained: Why Hangxiety Peaks and How Magnesium + L-Theanine Can Short-Circuit It - Reframe App, <https://www.joinreframeapp.com/articles/gaba-glutamate-rebound-hangxiety-magnesium-l-theanine-relief>
7. Dihydromyricetin: an emerging compound with comprehensive effects on multiple systems, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1488003/full>
8. Alcohol depletes coenzyme-Q10 associated with increased TNF-alpha secretion to induce cytotoxicity in HepG2 cells | Request PDF - ResearchGate, [https://www.researchgate.net/publication/230580979\\_Alcohol\\_depletes\\_coenzyme-Q10\\_associated\\_with\\_increased\\_TNF-alpha\\_secretion\\_to\\_induce\\_cytotoxicity\\_in\\_HepG2\\_cells](https://www.researchgate.net/publication/230580979_Alcohol_depletes_coenzyme-Q10_associated_with_increased_TNF-alpha_secretion_to_induce_cytotoxicity_in_HepG2_cells)
9. Neurotoxicity of Chronic Alcohol Exposure: Mechanistic Insights, Cellular Disruption, and Emerging Therapeutic Strategies - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12786252/>
10. Similarities in alcohol and opioid withdrawal syndromes suggest common negative reinforcement mechanisms involving the interoceptive antireward pathway - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8555739/>
11. Canadian Alcohol Use Disorder Guideline – CRISM, <https://crism.ca/alcohol-use-disorder/>
12. Guidelines for Treatment of Alcohol Withdrawal in Outpatient Settings - Canada's Drug Agency, <https://www.cda-amc.ca/sites/default/files/pdf/htis/2022/RB1638%20Guidelines%20AWS%20Final.pdf>
13. Alcohol Intoxication Withdrawal, Adult ED/UCC Order Set - Alberta Health Services, <https://www.albertahealthservices.ca/frm-20745-bond.pdf>
14. Moncton Addiction Services - Horizon Health Network - NB 211, <https://nb.211.ca/record-detail/72030882/>
15. Addiction services - gnb.ca, <https://www.gnb.ca/en/topic/health-wellness/addictions-substance-abuse/addiction-services.html>
16. Section 3.9 - New Brunswick | Substance Use Health Network, <https://www.substanceusehealth.ca/advocacy-toolkit-NB>
17. Intensive Day Treatment Program (IDT) - Horizon Health Network, <https://horizonnb.ca/services/addictions-mental-health/adult-services/intensive-day-treatment-program-idt/>
18. Natural Treatments of Alcohol and Drug Abuse and Withdrawal | Psychology Today, <https://www.psychologytoday.com/us/blog/integrative-mental-health-care/201901/natural-treatments-alcohol-and-drug-abuse-and-withdrawal>
19. What Herbs help with Alcohol Withdrawal? | AlcoholAwareness.org, <https://alcoholawareness.org/alcoholism/detox/medications/herbs/>
- 20.

Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medication ..., <https://pmc.ncbi.nlm.nih.gov/articles/PMC3292407/> 21. Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medication | Journal of Neuroscience, <https://www.jneurosci.org/content/32/1/390.short> 22. (PDF) Dihydromyricetin As A Novel Anti-Alcohol Intoxication Medication - ResearchGate, [https://www.researchgate.net/publication/51983987\\_Dihydromyricetin\\_As\\_A\\_Novel\\_Anti-Alcohol\\_Intoxication\\_Medication](https://www.researchgate.net/publication/51983987_Dihydromyricetin_As_A_Novel_Anti-Alcohol_Intoxication_Medication) 23. Identification of Dihydromyricetin and Metabolites in Serum and Brain Associated with Acute Anti-Ethanol Intoxicating Effects in Mice - MDPI, <https://www.mdpi.com/1422-0067/22/14/7460> 24. Dihydromyricetin - Alzheimer's Drug Discovery Foundation, [https://www.alzdiscovery.org/uploads/cognitive\\_vitality\\_media/Dihydromyricetin.pdf](https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Dihydromyricetin.pdf) 25. Dihydromyricetin improves mitochondrial outcomes in the liver of alcohol-fed mice via the AMPK/Sirt-1/PGC-1 $\alpha$  signaling axis | Request PDF - ResearchGate, [https://www.researchgate.net/publication/347400139\\_Dihydromyricetin\\_improves\\_mitochondrial\\_outcomes\\_in\\_the\\_liver\\_of\\_alcohol-fed\\_mice\\_via\\_the\\_AMPKSirt-1PGC-1a\\_signaling\\_axis](https://www.researchgate.net/publication/347400139_Dihydromyricetin_improves_mitochondrial_outcomes_in_the_liver_of_alcohol-fed_mice_via_the_AMPKSirt-1PGC-1a_signaling_axis) 26. Antialcohol Effects of Dihydromyricetin in Combination With Other Flavonoids, [https://www.researchgate.net/publication/343728529\\_Antialcohol\\_Effects\\_of\\_Dihydromyricetin\\_in\\_Combination\\_With\\_Other\\_Flavonoids](https://www.researchgate.net/publication/343728529_Antialcohol_Effects_of_Dihydromyricetin_in_Combination_With_Other_Flavonoids) 27. A multifaceted review on dihydromyricetin resources, extraction, bioavailability, biotransformation, bioactivities, and food app, <https://freidok.uni-freiburg.de/files/247957/rorthHw96Ko4g2pQ/eFood+-+2021+-+Zhang+-+A+m+ultifaceted+review+on+dihydromyricetin+resources++extraction++bioavailability++biotransformation+.pdf> 28. A multifaceted review on dihydromyricetin resources, extraction, bioavailability, biotransformation, bioactivities, and food app - Semantic Scholar, <https://pdfs.semanticscholar.org/f33c/f018d624c7d2f58e19efb1554c1a41efe6cb.pdf> 29. A Single Dose of Kudzu Extract Reduces Alcohol Consumption in a Binge Drinking Paradigm - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4510012/> 30. Kudzu Root Reduces Alcohol Consumption, <https://hams.cc/kudzu/> 31. Herbal Treatment for Alcohol Abuse: What to Consider - MAT Recovery Centers in USA: Addiction & Mental Health Care, <https://matrecoverycenters.com/blog/herbal-treatment-for-alcohol-abuse-what-to-consider/> 32. NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT<sub>2C</sub> agonists - PubMed, <https://pubmed.ncbi.nlm.nih.gov/12895679/> 33. A Standardized Kudzu Extract (NPI-031) Reduces Alcohol Consumption in Non Treatment-Seeking Male Heavy Drinkers - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3562758/> 34. Skullcap plants - Shopping | Kailash Herbs, <https://www.kailashherbs.co.nz/skullcap-plants> 35. Skullcap - Red Clover Herbal Apothecary Farm, <https://redcloverapothecary.com/skullcap/> 36. Skullcap, Mad Dog - Herb Seeds | The Thyme Garden, <https://www.thymegarden.com/product-page/skullcap-mad-dog-herb-seeds> 37. Ocular and Systemic Pharmacokinetics of Baicalein and Baicalin After Intravitreal Injection and Oral Administration in Mice - MDPI, <https://www.mdpi.com/1999-4923/18/2/243> 38. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation - Dove Medical Press, <https://www.dovepress.com/article/download/14548> 39. BAICALEIN - Inxight Drugs, <https://drugs.ncats.io/drug/49QAH60606> 40. Inhibitory effect of Erigeron breviscapus extract and its flavonoid components on GABA shunt enzymes - PubMed, <https://pubmed.ncbi.nlm.nih.gov/17689232/> 41. Baicalin and baicalein from Scutellaria baicalensis Georgi alleviate aberrant neuronal suppression mediated by GABA from reactive astrocytes - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11076983/> 42. herb Article Skullcap - Rebecca's Herbal Apothecary, <https://www.rebeccasherbs.com/pages/herb-article-br-skullcap>

43. Human disposition of L-theanine in tea or aqueous solution - Gwern.net, <https://gwern.net/doc/tea/2010-vanderpijl.pdf> 44. Expert Opinion: L-theanine and Alcohol - Everything You Need To Know, <https://drinkmoment.com/blogs/moment-blog/expert-opinion-l-theanine-and-alcohol-everything-you-need-to-know> 45. Clinical assessment of blood glucose responses to 300-mg dose of L-theanine, an amino acid unique to green tea, in a fixed-sequence, two-period trial - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC13113039/> 46. Sulforaphane Bioavailability from Glucoraphanin-Rich Broccoli: Control by Active Endogenous Myrosinase - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4629881/> 47. Sulforaphane Bioavailability in Healthy Subjects Fed a Single Serving of Fresh Broccoli Microgreens. | Linus Pauling Institute, <https://lpi.oregonstate.edu/publications/sulforaphane-bioavailability-healthy-subjects-fed-single-serving-fresh-broccoli> 48. Bioavailability and Kinetics of Sulforaphane in Humans after Consumption of Cooked versus Raw Broccoli | Journal of Agricultural and Food Chemistry - ACS Publications, <https://pubs.acs.org/doi/10.1021/jf801989e> 49. Study Details | NCT04946526 | Broccoli Sulforaphane Bioavailability With Mustard, <https://clinicaltrials.gov/study/NCT04946526> 50. Dihydromyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7127391/> 51. Enhancing Bioavailability of Dihydromyricetin through Inhibiting Precipitation of Soluble Cocrystals by a Crystallization Inhibitor - ACS Publications, <https://pubs.acs.org/doi/10.1021/acs.cgd.6b00591> 52. Full article: Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine - Taylor & Francis, <https://www.tandfonline.com/doi/full/10.1080/10717544.2019.1660732> 53. Bioavailability - Cheers, <https://cheershealth.com/blog/bioavailability> 54. Identification of Dihydromyricetin and Metabolites in Serum and Brain Associated with Acute Anti-Ethanol Intoxicating Effects in Mice - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8307506/> 55. Gastric floating sustained-release tablet for dihydromyricetin - ScienceOpen, [https://www.scienceopen.com/document\\_file/3b84688e-884a-4a0f-abd7-1c5082180dca/PubMedCentral/3b84688e-884a-4a0f-abd7-1c5082180dca.pdf](https://www.scienceopen.com/document_file/3b84688e-884a-4a0f-abd7-1c5082180dca/PubMedCentral/3b84688e-884a-4a0f-abd7-1c5082180dca.pdf) 56. Absolute oral bioavailability and disposition kinetics of puerarin in female rats - PubMed, <https://pubmed.ncbi.nlm.nih.gov/29801513/> 57. Comparative Pharmacokinetics of Puerarin Alone and in Pueraria mirifica Extract in Female Cynomolgus Monkeys - Who we serve, <https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-1271-7092.pdf> 58. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine - Taylor & Francis, <https://www.tandfonline.com/doi/abs/10.1080/10717544.2019.1660732> 59. Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes - PMC - NIH, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4128791/> 60. Characterization and Bioavailability Study of Baicalin- mesoporous Carbon Nanopowder Solid Dispersion - Pharmacognosy Magazine, <https://phcog.com/article/sites/default/files/PhcogMag-12-48-326.pdf> 61. Role of Intestinal Microbiota in Baicalin-Induced Drug Interaction and Its Pharmacokinetics, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6273104/> 62. Development and evaluation of a novel nebulized dihydromyricetin formulation: enhanced pulmonary delivery and pharmacokinetic properties - PMC, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12706889/> 63. Improved Activity of Herbal Medicines through Nanotechnology - PMC - NIH, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9695685/> 64. Enhanced oral bioavailability of baicalein using phospholipid-coated nanoparticles: A novel drug delivery system, [https://wjbps.com/sites/default/files/fulltext\\_pdf/WJBPHS-2025-0842.pdf](https://wjbps.com/sites/default/files/fulltext_pdf/WJBPHS-2025-0842.pdf) 65. Effects of

baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition - IMR Press,  
[https://storage.imrpress.com/IMR/pharmazie/application/64\\_09\\_S579\\_583.pdf](https://storage.imrpress.com/IMR/pharmazie/application/64_09_S579_583.pdf)